1. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies
- Author
-
Vito R. Petretta, L. Passamano, Giugliano Ma, Vincenzo Nigro, Antonella Pini, Giovanni Nigro, Marina Mora, Comi Li, L. Politano, Pasquale Raia, Ge Nigro, P.F Rambaldi, Serenella Papparella, Maria Esposito, Politano, Luisa, Nigro, Vincenzo, Passamano, L, Petretta, V, Comi, Li, Papparella, S, Nigro, Gerardo, Rambaldi, Pier Francesco, Raia, P, Pini, A, Mora, M, Giugliano, Ma, Esposito, Mg, Nigro, G., Politano, L, Nigro, V, Papparella, Serenella, Nigro, G, and Rambaldi, Pf
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,DNA Mutational Analysis ,Cardiomyopathy ,Alpha (ethology) ,Muscular Dystrophies ,Sarcoglycans ,Internal medicine ,Humans ,Medicine ,Respiratory system ,Child ,Muscle, Skeletal ,Genetics (clinical) ,Tomography, Emission-Computed, Single-Photon ,Membrane Glycoproteins ,business.industry ,Myocardium ,Skeletal muscle ,Dilated cardiomyopathy ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Respiratory Function Tests ,Cytoskeletal Proteins ,Phenotype ,medicine.anatomical_structure ,Sarcoglycanopathy ,Neurology ,Child, Preschool ,Mutation ,Pediatrics, Perinatology and Child Health ,Cardiology ,Female ,Neurology (clinical) ,Cardiomyopathies ,Respiratory Insufficiency ,business ,Sarcoglycanopathies - Abstract
Sarcoglycanopathies constitute a subgroup of limb-girdle recessive muscular dystrophies due to defects in sarcoglycan complex that comprises five distinct transmembrane proteins called alpha-, beta-, gamma-, delta-and epsilon-sarcoglycans. As it is well known that sarcoglycans are expressed both in heart and in skeletal muscles and a complete deficiency in delta-sarcoglycan is the cause of the Syrian hamster BIO.14 cardiomyopathy, we studied cardiac and respiratory involvement in 20 patients with sarcoglycanopathies by clinical, electrocardiographic, echocardiographic, scintigraphic and spirometric assessments. A normal heart function was found in 31.3% of all patients; a preclinical cardiomyopathy in 43.7%; an arrhythmogenic cardiomyopathy in 6.3% and initial signs of dilated cardiomyopathy in 18.7%. In one patient the data were examined retrospectively. No correlation was found between cardiac and skeletal muscle involvement. With reference to the type of sarcoglycanopathy, signs of hypoxic myocardial damage occurred in beta-, gamma- and delta-sarcoglycanopathies, while initial signs of a dilated cardiomyopathy in gamma- and delta-sarcoglycanopathies were found. A normal respiratory function was observed in 23.5% of all patients, a mild impairment in 35.4%, a moderate impairment in 29.4%, and a severe impairment in 11.7%.
- Published
- 2001